Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,352.00
Bid: 12,352.00
Ask: 12,356.00
Change: -46.00 (-0.37%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,482.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

A quarter of symptomatic kids hit by long COVID; mRNA shots provide best protection in breast milk

Mon, 14th Mar 2022 18:42

March 14 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

One in four kids with COVID develop lingering problems

One in four children with COVID-19 symptoms develop "long COVID," according to data pooled from 21 earlier studies conducted in Europe, Asia, Australia and South America.

Among the 80,071 children with COVID-19 in the studies, 25% developed symptoms that lasted at least 4-to-12 weeks or new persistent symptoms that appeared within 12 weeks, researchers reported on Sunday on medRxiv https://www.medrxiv.org/content/10.1101/2022.03.10.22272237v1 ahead of peer review. The most frequent problems were neuropsychiatric (mood symptoms, fatigue, sleep disorders, headaches, cognitive alterations, dizziness, balance problems), cardiorespiratory (breathing difficulty, congestion, exercise intolerance, chest pain and tightness, cough, irregular heart rhythm), skin-related (excessive sweating, itchiness, hair loss) and gastrointestinal (abdominal pain, constipation, diarrhea, vomiting, and nausea). Analyses of data pooled from many different studies with different methodologies cannot yield firm conclusions, the researchers acknowledge. What is clear, however, is that "children and adolescents have also physical and mental health consequences derived from COVID-19," said study coauthor Sonia Villapol of Houston Methodist Research Institute in Texas.

"Identifying the main signs and symptoms of pediatric long COVID can help diagnose, develop better treatments, create multidisciplinary teams for optimal clinical management, and find risk factors for prevention."

Vaccine protection in mother's milk strongest after mRNA shots

Women who wish to pass protective antibodies induced by COVID-19 vaccines to their babies via breast milk should opt for the mRNA shots from Moderna or Pfizer/BioNTech , according to a study reported on Monday in JAMA Pediatrics https://jamanetwork.com/journals/jamapediatrics/fullarticle/2789947.

For the study, 124 lactating women each provided 17 milk samples over a period of 100 days. The women had received either an mRNA vaccine or a vector-based vaccine from Johnson & Johnson or AstraZeneca. Researchers measured two types of antibodies in the milk samples - IgA antibodies and IgG antibodies, both of which are thought to play important roles in protecting breastfed infants. Nearly all - 96% to 97% - of the women who received both doses of an mRNA vaccine had detectable IgA antibodies in their milk, while only 39% had antibodies in their milk after two doses of the AstraZeneca shot and 48% after the one-dose J&J vaccine. All the women who received both doses of the Pfizer/BioNTech, Moderna or AstraZeneca vaccines had IgG antibodies, compared to only 28% of women who received J&J's shot.

"An mRNA-based COVID-19 vaccine is the optimal choice for lactating women when they want to transfer breast milk antibodies to their infants," the researchers concluded.

Omicron is infectious on surfaces longer than original virus

Omicron particles remain infectious on surfaces for longer periods than particles of the original SARS-CoV-2, according to laboratory experiments.

Researchers put droplets of infectious virus from the original coronavirus version and the Omicron BA.1 variant on a variety of surfaces at room temperature. On smooth surfaces (glass, stainless steel and plastic sheet), Omicron was still infectious after seven days, whereas particles of the original SARS-CoV-2 were no longer infectious on stainless steel and plastic sheets by day 4 and on glass by day 7, the researchers reported on Thursday on bioRxiv https://www.biorxiv.org/content/10.1101/2022.03.09.483703v1 ahead of peer review. On tissue paper and printing paper, the original virus was no longer infectious at 30 minutes. Omicron was still infectious at 30 minutes, but no longer after an hour, the researchers said.

For the most part, SARS-CoV-2 is transmitted via respiratory droplets in the air. While infection via contact with contaminated surfaces is less common, the new study "highlights the importance of hand hygiene and cleaning on surfaces that are regularly touched by different persons," said study coauthor Leo Poon of the University of Hong Kong. "For surfaces and settings contaminated by a COVID-19 patient, proper cleaning should be done."

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

More News
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.